Main Uses of Donnatal Extentabs

Donnatal Extentabs is a combination medication formulated to manage various gastrointestinal disorders. It is primarily used as adjunctive therapy in the treatment of conditions characterized by smooth muscle spasms and hypermotility in the digestive tract.

Irritable Bowel Syndrome (IBS)

One of the primary applications of Donnatal Extentabs is the management of irritable bowel syndrome. In this context, the medication is used to help reduce the frequency and intensity of abdominal cramping and discomfort. By addressing the underlying muscle spasms in the colon, it helps stabilize bowel movement patterns in patients experiencing functional bowel disturbances.

Acute Enterocolitis

The medication is also utilized in the treatment of acute enterocolitis. It serves to soothe the inflammation-related spasms of the intestinal lining, which can help alleviate the urgency and cramping associated with these episodes.

Peptic Ulcer Disease

While not a primary treatment for ulcers, Donnatal Extentabs may be used as an adjunct therapy in the management of duodenal or gastric ulcers. Its role involves reducing gastric motility and secretion, which can provide a more stable environment for the primary ulcer treatments to function and help manage the associated pain caused by stomach contractions.

Potential Benefits

Antispasmodic Activity

The core benefit of Donnatal Extentabs is its antispasmodic effect. The combination of belladonna alkaloids works to relax the smooth muscles of the gastrointestinal tract. This relaxation is essential for relieving the localized pain and pressure that occur when these muscles contract excessively or irregularly.

Reduction of Gastrointestinal Motility

For patients suffering from conditions that cause the digestive system to move too quickly, this medication helps slow down these processes. By modulating the speed of transit through the gut, it can help reduce the frequency of bowel movements and the associated physical exhaustion often reported by patients with hypermotile conditions.

Anticholinergic Effects

The medication also possesses mild sedative and anticholinergic properties due to the inclusion of phenobarbital and specific alkaloids. This combination is intended to address both the physical spasms and the mild anxiety or tension that often accompanies chronic gastrointestinal distress, contributing to an overall stabilization of the digestive system.

Regulatory References

1. Donnatal Extentabs - DailyMed (NIH/NLM)

Who Can and Cannot Use Donnatal Extentabs?

The official eligibility profile for Donnatal Extentabs is strictly defined by government regulatory documents, focusing on populations with specific, high-risk conditions who must not use the medicine.

Contraindicated Populations

Use is absolutely contraindicated in patients with conditions that include:

• Glaucoma or Acute Intermittent Porphyria.
• Obstructive Disease of the gastrointestinal tract (e.g., paralytic ileus, pyloroduodenal stenosis).
• Obstructive Uropathy (e.g., bladder neck obstruction).
• Intestinal Atony in the elderly or debilitated patient.
• Known Hypersensitivity to any of the four active ingredients.

Restricted and Conditional Use

Certain populations require caution and close oversight due to an increased risk of complications. This includes patients with:

• Cardiovascular conditions (e.g., coronary heart disease, tachycardia, congestive heart failure).
• Hepatic or Renal Dysfunction.
• Hyperthyroidism or Autonomic Neuropathy.

Age and Physiological Status

• Pediatric Use is not formally established in the prescribing information.
• For Pregnancy, the medicine is classified as Category C and should be administered only if clearly needed.

Interactions with other medicines and products

Official regulatory documentation details interaction patterns arising from both pharmacokinetic and pharmacodynamic mechanisms.

Exposure-Altering Interactions

The Phenobarbital component is classified as a hepatic enzyme inducer. This pharmacokinetic interaction can decrease the therapeutic effect of anticoagulants such as warfarin, potentially necessitating a higher dose of the anticoagulant while co-administered. This same enzyme induction may reduce the effectiveness of hormonal birth control products (e.g., pills, patches) by increasing their clearance.

An absorption-based interaction occurs with antacids, which can decrease the absorption of the belladonna alkaloids. To mitigate this effect, the official label requires a mandatory timing separation rule: antacids must be taken at least 3 hours before or 3 hours after this medication.

Pharmacodynamic Interactions

Co-administration with alcohol or other Central Nervous System (CNS) depressants (e.g., sedatives, narcotic pain medicines) results in an additive CNS depressant effect. This reinforcement increases the sedative property of the medicine. Likewise, co-use with other anticholinergic agents may increase the risk of adverse effects due to an additive pharmacodynamic burden.

Population-Specific Notes

Caution is required for patients with hepatic dysfunction due to the liver's role in clearing Phenobarbital. To account for potentially slower metabolism in this population, small initial doses are required. The herbal product St. John's Wort is also listed among substances that require consideration due to its interaction profile.

Donnatal Extentabs' mechanism involves two distinct pharmacological actions from its components: belladonna alkaloids (hyoscyamine, atropine, scopolamine) and phenobarbital.

• Belladonna Alkaloids: These agents function as competitive antagonists at peripheral muscarinic acetylcholine receptors (mAChRs), particularly subtypes M1, M2, and M3, located on postganglionic parasympathetic effector cells in the gastrointestinal (GI) and urinary tracts. Binding to these receptors prevents the activation by endogenous acetylcholine, which is the primary neurotransmitter of the parasympathetic system. The resulting inhibition of cholinergic signaling reduces the intracellular cascade that typically leads to smooth muscle contraction and glandular secretion. The system-level physiological consequence is a decrease in GI motility, a reduction in the tone and frequency of smooth muscle contractions (antispasmodic action), and decreased production of gastric, salivary, and bronchial secretions.

• Phenobarbital: This barbiturate acts as a positive allosteric modulator on the neuronal GABAA receptor complex in the central nervous system (CNS). Binding to its distinct site on the receptor increases the duration for which the integral chloride ion channel remains open following gamma-aminobutyric acid (GABA) binding. The resulting sustained influx of chloride ions hyperpolarizes the postsynaptic membrane, thus elevating the threshold for action potential generation. This molecular action leads to generalized CNS depression, which modulates neuronal excitability and transmission.

The instructions for using Donnatal Extentabs (extended-release tablets) define a specific oral administration and dosing regimen. As a combination medication, the dosage is adjusted to the patient’s individual needs to ensure symptomatic control with minimal adverse reactions.

Official Administration Guidelines

Administration Scope	Detail
Route of Administration	Oral (by mouth)
Dosing Schedule (Adults)	One tablet every twelve (12) hours. If clinically indicated, one tablet every eight (8) hours may be given.
Preparation Requirements	The tablet must be swallowed whole; it is designed to release ingredients gradually for up to twelve hours. Do not crush, cut, or chew the extended-release tablet.
Timing in Relation to Meals	Take with or without food. Taking the dose with food may be recommended if the medication causes an upset stomach.

Rules for Missed Doses

If a dose is missed, the guidance is to take the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped entirely, and the patient should return to the regular dosing schedule. It is advised not to take two doses or extra doses at the same time to compensate for a missed one.

Procedural Summary

This medication is a sustained-release formulation, which necessitates swallowing the tablet intact. The typical frequency is two doses per day to maintain a steady level of the active ingredients. The need for dosage adjustment underscores that the administration protocol is personalized.

Donnatal Extentabs: Recent Clinical Evidence

The formulation known as Donnatal Extentabs is an extended-release combination of four active ingredients: the antispasmodic belladonna alkaloids (hyoscyamine, atropine, and scopolamine) and the sedative phenobarbital.

Historically, the U.S. Food and Drug Administration (FDA) reviewed the fixed combination products containing belladonna alkaloids and phenobarbital under regulatory changes implemented after 1962. Based on a review by the National Academy of Sciences-National Research Council (NAS-NRC), the FDA classified the use of these drug combinations as “possibly” effective as adjunctive therapy for the symptomatic treatment of irritable bowel syndrome (IBS) and acute enterocolitis.

---

Evaluation of Outcomes in Gastrointestinal Disorders

Clinical trials involving fixed combinations of belladonna alkaloids and phenobarbital have explored their potential role in managing functional gastrointestinal disorders. Early research, including randomized double-blind studies, documented a greater percentage of patients reporting improvement in symptoms like abdominal pain and bowel habits when receiving the combination therapy compared to those receiving a placebo.

---

Safety and Long-Term Data

Extended-release formulations are designed to maintain therapeutic levels for up to 12 hours. Long-term use necessitates careful monitoring, primarily due to the inclusion of phenobarbital, which may pose a risk for physical or psychological dependence and can cause withdrawal symptoms if abruptly discontinued. The belladonna alkaloids in the medication can also impair the body's ability to regulate temperature, potentially leading to fever or heatstroke, especially in high environmental temperatures. Safety data emphasizes that the medication is contraindicated in patients with conditions like glaucoma, obstructive uropathy, and obstructive disease of the gastrointestinal tract.

Key Studies & References

1. Donnatal Extentabs DailyMed Label (phenobarbital, hyoscyamine sulfate, atropine sulfate, scopolamine hydrobromide)
2. Belladonna Alkaloid Combinations and Phenobarbital: MedlinePlus Drug Information (for mechanism, side effects, and warning context)

Common questions about Donnatal Extentabs (FAQ)

Q: What is Donnatal Extentabs typically used for?

A: Donnatal Extentabs is approved as adjunctive therapy in the treatment of irritable bowel syndrome (IBS) and acute enterocolitis. Adjunctive therapy means it is used along with other treatments, such as diet or other medications.

Q: How does the "Extentabs" part relate to the medication?

A: The "Extentabs" name indicates that the tablet formulation is extended-release. This design is intended to allow the active ingredients to be released slowly over a period of time, which may allow for less frequent dosing.

Q: Can Donnatal Extentabs be stopped suddenly?

A: Because Donnatal Extentabs contains phenobarbital, a barbiturate, stopping treatment abruptly after long-term use may be associated with withdrawal symptoms. Healthcare providers generally recommend a gradual reduction in dosage when discontinuation is necessary.

Q: Are there any known serious side effects or warnings?

A: Due to the combination of ingredients, there are several warnings. The label indicates that it should not be used if a person has glaucoma, certain urinary tract obstructions, or severe ulcerative colitis. Additionally, phenobarbital may be habit-forming and has a risk of dependence. A healthcare professional can provide a complete review of all warnings and contraindications.

Donnatal Extentabs must be stored at Controlled Room Temperature, which is defined as 20^circC to 25^circC (68^circF to 77^circF).

Storage Conditions and Packaging

This medication must be protected from light and moisture to maintain its stability and should be dispensed in a well-closed, light-resistant container. The packaging is required to use a child-resistant closure. For safety, the product must be kept out of the reach of children.

---

Disposal Instructions

To dispose of unused or expired Donnatal Extentabs, the official recommendation is to use a drug take-back program. If one is unavailable, the medication should be mixed with an undesirable substance (e.g., dirt or used coffee grounds), sealed in a container, and placed in the household trash. The product is not on the U.S. FDA's list of medicines recommended for flushing.